Palvella Therapeutics (PVLA) Other Non-Current Liabilities (2013 - 2026)
Palvella Therapeutics (PVLA) posted quarterly Other Non-Current Liabilities of $2.2 million for Q1 2026, up 25.26% year-over-year from $1.7 million in Q1 2025, and up 5.68% quarter-over-quarter from $2.0 million in Q4 2025.
Palvella Therapeutics (PVLA) Other Non-Current Liabilities (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Other Non-Current Liabilities for 12 consecutive years, with $2.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 25.26% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $2.2 million (up 25.26% YoY), while the FY2025 annual figure was $2.0 million, up 23.92% from the prior year.
- Other Non-Current Liabilities grew to $2.2 million in Q1 2026 per PVLA's latest filing, from $2.0 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $2.2 million in Q1 2026 and bottomed at $1.0 million in Q4 2023.
- Historically, Other Non-Current Liabilities has averaged $1.8 million across 4 years, with a median of $1.8 million in 2025.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities jumped 62.43% — and 2025, when it gained 23.92%.
- Palvella Therapeutics' Other Non-Current Liabilities stood at $1.0 million in 2023, then surged by 62.43% to $1.6 million in 2024, then rose by 23.92% to $2.0 million in 2025, then rose by 5.68% to $2.2 million in 2026.
- Business Quant data shows PVLA's Other Non-Current Liabilities at $2.2 million in Q1 2026, $2.0 million in Q4 2025, and $1.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Palvella Therapeutics | 2.25 Bn | 1.93 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.27 Mn |
| Mar 31, 2026 | 2.16 Mn |
| Dec 31, 2025 | 2.04 Mn |
| Sep 30, 2025 | 1.92 Mn |
| Jun 30, 2025 | 1.84 Mn |
| Mar 31, 2025 | 1.72 Mn |
| Dec 31, 2024 | 1.65 Mn |
| Dec 31, 2023 | 1.01 Mn |
| Dec 31, 2020 | 6,000.00 |
| Sep 30, 2019 | 12.08 Mn |
| Jun 30, 2019 | 12.32 Mn |
| Mar 31, 2019 | 27,000.00 |
| Dec 31, 2018 | 27,000.00 |
| Sep 30, 2018 | 32,000.00 |
| Jun 30, 2018 | 37,000.00 |
| Mar 31, 2018 | 37,000.00 |
| Dec 31, 2017 | 37,000.00 |
| Sep 30, 2017 | 43,462.00 |
| Jun 30, 2017 | 42,862.00 |
| Mar 31, 2017 | 42,086.00 |